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-Catenin is a multifunctional protein, stabilization of which is a
critical step in its functional activity. Stabilization can be conferred
through several means, including mutations in -catenin, common
in many carcinomas. In this article, we explore the effect of viral
infection on the -catenin signaling pathway in B lymphocytes,
including cell lines derived from lymphomas. Infection by the
human tumor virus Epstein–Barr virus (EBV) generates several
types of latency with different spectra of latent gene expression
that are associated with different malignancies. In type III latency,
exemplified by EBV lymphoproliferative diseases, the full range of
these viral proteins is expressed, whereas in type I latency, only the
EBNA1 protein is expressed and functional. We show that -cate-
nin is rapidly degraded in type I B lymphocytic lines but it is
stabilized in type III B cell lines, and that -cateninT cell factor
transcriptional activity is significantly higher in type III cells. Also
we show the association of free cytoplasmic -catenin with deu-
biquitinating enzymes, which may play a role in -catenin stabi-
lization. Activation of the -cateninT cell factor pathway by EBV
may contribute to the lymphoproliferation characteristic of type III
latency.
The multifunctional protein -catenin plays a dual role in cellsas a major structural component of cell–cell adherens junc-
tions and as a signaling molecule in the Wnt pathway. The
nonjunctional pool of -catenin is normally degraded by the
ubiquitin-proteasome system or, under certain conditions such
as the activation of Wnt signaling, -catenin is not degraded but
stabilized, and it then activates transcription by providing a
transactivation domain in a heterodimeric complex with lym-
phoid enhancer factor (Lef)T cell factor (Tcf) transcription
factors (1).
The amount of uncomplexed cytoplasmic -catenin is gener-
ally regulated by a multiprotein complex including glycogen
synthase kinase 3 (GSK3), the adenomatous polyposis coli
(APC) tumor suppressor protein, and Axin (2, 3). This complex
targets -catenin for phosphorylation, which triggers its ubiq-
uitination and degradation.
Epstein–Barr virus (EBV) infects and immortalizes B lym-
phocytes, and the viral genome is regularly detected in a number
of lymphoid malignancies (4, 5). EBV can establish different
latency states in B lymphocytes. In type I latency, found in
Burkitt’s lymphoma, EBV nuclear antigen-1 (EBNA-1) is the
chief gene product to be expressed. In type III latency, exem-
plified by EBV lymphoproliferative diseases, all of the viral
latency proteins (six EBNAs and three lymphocyte membrane
proteins) are expressed (6). It has been shown that EBNA2,
which is expressed only in type III latency, induces c-Myc and
cyclin D expression (7). -Catenin also is involved in activation
of these genes (8, 9).
Studies in recent years have shown that -catenin is a potential
oncogene, and its accumulation has been implicated in a variety
of carcinomas (1, 10). The -cateninTcf pathway also is signif-
icant in lymphocyte proliferation and differentiation during
embryonic development in mice (11), and Wnt signaling plays an
important role in self-renewal of hematopoietic stem cells (12).
However, the possible effect of virus infection on the pathway
has received little attention, and the role of the -cateninTcf
pathway in B cell lymphomas is largely unknown.
Ubiquitination is an essential step for proteasomal degrada-
tion. The identification and characterization of enzymes that
recognize and ubiquitinate the substrates has been a major focus
in the ubiquitin-proteasome field (13). Recently, interest in their
enzymatic opposites, the deubiquitinating enzymes (DUBs), has
rapidly emerged (14, 15). The presence of a large number of
tissue-specific DUBs that share little sequence similarity sug-
gests an as yet largely unexplored substrate specificity of this
class of proteins (16).
It was shown recently that the herpesvirus-associated ubiq-
uitin-specific protease can remove ubiquitin from the p53 tumor
suppressor protein and rescue it from degradation, leading to
p53-mediated cell-growth repression (17), and the tumor sup-
pressor CYLD [which is mutated in familial cylindromatosis
(18)], turns out to be a DUB that negatively regulates NF-B
signaling (19, 20). Yet knowledge about substrates of DUBs and
their biological role in cells is otherwise very limited. Recently
a new method for labeling active DUBs was reported (21) that
will be helpful for study of the biological role of this family of
proteins.
In this article, we show that type III latent EBV infection leads
to -catenin stabilization and activation in EBV-infected lym-
phoid cell lines, whereas type I latency does not. We found
further that free cytoplasmic -catenin is associated with active
DUBs.
Materials and Methods
Cell Lines and Reagents. All cell lines were cultured in RPMI
medium 1640 (GIBCO) supplemented with 10% FBS (Sigma),
penicillin, and streptomycin.
MG132 (benzyloxycarbonyl-leu-leucinyl-leucinal) and
MG101 (N-acetyl-leu-leu-norleucinal) were obtained from Cal-
biochem. TCF reporter plasmids were obtained from Upstate
Biotechnology (Lake Placid, NY). Ubiquitin aldehyde (Ubal)
and protein AG PLUS-Agarose were obtained from Santa Cruz
Biotechnology.
Antibodies. -Catenin (Transduction Laboratories, Lexington,
KY), Axin (Zymed), GSK3 (Transduction Laboratories), APC
(c-20; Santa Cruz Biotechnology), Tcf-4 (clone 6H5–3; Upstate
Biotechnology), actin (Sigma), and hemagglutinin (HA) tag
(F-7; Santa Cruz Biotechnology). Antibodies were used at the
indicated dilutions.
Abbreviations: EBV, Epstein–Barr virus; Tcf, T cell factor; GSK, glycogen synthase kinase;
APC, adenomatous polyposis coli; DUB, deubiquitinating enzyme; HA, hemagglutinin;
Ubal, ubiquitin aldehyde.
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Western Blotting. Cells were lysed in lysis buffer [50 mM Hepes, pH
7.4150 mM NaCl10% glycerol1 mM EDTA1 mM sodium
orthovanadate100 mM NaF1% Triton X-100protease inhibitor
mixture (Roche Diagnostics)]. Protein concentration was deter-
mined by the Bradford assay (Bio-Rad). Total cell proteins
were resolved on SDS10% PAGE, transferred to nitrocellulose
membrane (Osmonics, Minnetonka, MN), blocked in 5% milk
Tris-buffered saline, and incubated overnight with -catenin
(1:500), Tcf (1:250), and actin (1:10,000) antibodies.
Northern Blotting. Total RNAs of Sav I and Sav III cells were
separated by electrophoresis on 1% agarose gels containing
3.7% formaldehyde; equal loading was assessed by analysis of the
rRNA band on ethidium bromide-stained gels. Total RNA was
transferred on nylon membrane and crosslinked by UV light.
The Northern blots were probed with biotin-labeled cDNA
specific for -catenin according to the manufacturer’s protocol
(Ambion, Austin, TX). The blots then were washed twice with
2 SSPE (20 SSPE consists of 0.2 M sodium phosphate, pH
7.4, containing 25 mM EDTA and 3 M NaCl) at room temper-
ature, twice with 2 SSPE containing 1% SDS at 55°C, and
twice with 0.2 SSPE at room temperature. -Catenin mRNA
was detected with a nonisotopic detection kit (Ambion) accord-
ing to the protocol.
Immunoprecipitation. Whole-cell lysates were precleared with
AG PLUS-Agarose beads for 1 h at 4°C and incubated with the
indicated antibodies [Axin (1:500) or HA tag (1:100)] or an equal
amount of control Ig overnight at 4°C and then with beads for
an additional 1 h at 4°C. After intensive washing and centrifu-
gation, immune complexes were separated by SDSPAGE and
probed with antibodies to the following proteins as indicated:
GSK3 (1:1,000), APC (1:500), Axin (1:1,000), and -catenin
(1:500).
Reporter Assay. Approximately 107 Sav I or Sav III cells per
transfection were electroporated in 0.5 ml of RPMI medium
1640 (10% FBS) with a Bio-Rad Gene-Pulser at 260 V and 975
F. For reporter assays, each transfection contained 10 g of the
TOPFLASH or FOPFLASH plasmids. After electroporation,
cells were resuspended in 10 mM of complete medium and
incubated at 37°C. A -galactosidase-expressing vector was
included as an internal control for transfection efficiency. Forty-
eight hours later, cells were collected and luciferase reporter
assays were performed according to standard procedures (Pro-
mega). Relative light units were measured in an Lmax luminom-
eter (Autolumat LB953; Perkin–Elmer).
Labeling Cells with HAUbVME and Ubal. Sav III cells were lysed in
labeling buffer (50 mM Tris, pH 7.45 mM MgCl2250 mM
sucrose1 mM DTT2 mM ATP). Nuclei and debris were
removed by centrifugation, and cell extracts were incubated with
HAUbVME probe (0.2 gl) for 1 h at 37°C or with 1 M Ubal
for 2 h at 37°C.
Results and Discussion
To investigate whether there are differences in -catenin protein
levels in either type I or type III latency, we examined several B
cell lines with different latency types by using a human kidney
epithelial cell line (293) that expresses high levels of -catenin
as a positive control. Western analysis shows a greater accumu-
lation of -catenin in type III latency than in type I (Fig. 1a). We
then looked at -catenin levels in the B cell lines Sav I and Sav
III. These cell lines are genetically identical, differing in their
EBV latency status, type I and type III, respectively (22). The
level of -catenin in Sav III is significantly higher than in Sav I,
implying that a type III latency product(s) influences -catenin
accumulation (Fig. 1b). We also tested for -catenin RNA levels
by Northern analysis and detected no significant difference in
type I and type III cells (Fig. 1c).
To determine whether the low level of -catenin detected in
type I cells was caused by proteasomal degradation, we incubated
cells with MG132, a potent proteasome inhibitor, and then
performed Western blot analysis. In all three latency type I cell
lines tested, significant accumulation of -catenin was detected
in the presence of the inhibitor. In contrast, in type III cells
-catenin was not further stabilized by MG132 (Fig. 2). There-
fore, the difference in -catenin levels between type I and type
III cell lines is attributable not to differential expression but to
differential degradation.
It has been shown that stabilized -catenin forms a complex
with Tcflymphoid enhancer factor transcriptional factors and
that this complex transactivates downstream targets such as
c-myc and cyclin D1. These genes have been implicated in cell
transformation and tumor development (8, 9). To investigate
whether stabilization of -catenin in latency III results in
transcriptional activation of Tcf, we transfected Sav I and Sav III
cell lines with Tcf reporter plasmids containing three copies of
WT Tcf-binding site (TOPFLASH) and three copies of mutated
site as a negative control (FOPFLASH). The results show that
stabilization of -catenin in type III latency leads to constitutive
transcriptional activation of -cateninTcf complex, as deter-
mined by the luciferase assay (Fig. 3a), and that transcriptional
activity of -catenin does not depend on the Tcf-expression level
in type I and type III latency (Fig. 3b).
Fig. 1. -Catenin expression in different types of latency in EBV-infected B
cell lines. (a) Total lysates of lines with type I latency (Akata and Rael) and type
III latency (X 50-7 and W 91) were resolved in 10% PAGE and probed with
-catenin and actin antibodies. Total extract from the 293 cell line was used as
the positive control for -catenin expression. (b) Total protein extracts of
genetically identical B cell lines with type I and type III latency (Sav I and Sav
III) were probed with -catenin and actin antibodies. (c) Northern blot of total
RNA extracts of Sav I and Sav III cells was probed with biotin-labeled -catenin
DNA probe.
Fig. 2. Proteasome inhibition causes -catenin accumulation in type I la-
tency. Cells were treated with 10 M MG132 for 1 h at 37°C before collection.
Western blots of total protein extracts from B cell lines were probed with
-catenin and actin antibodies.








The -catenin phosphorylation complex, the action of which
targets -catenin for degradation, has at least three essential
components: Axin, APC, and GSK3 (10). Recently it was
shown that the Kaposi’s sarcoma-associated herpesvirus latency-
associated nuclear antigen can dysregulate this complex by
binding to GSK3 (23). To test whether there are any differences
in the phosphorylation complex in type I and type III latency, we
isolated by immunoprecipitation the complex components with
Axin antibody. All three expected components were detected,
and there was no difference between the complexes detected in
the Sav I and Sav III cell lines (Fig. 4a). Therefore the destruc-
tion complex is structurally intact in lines of either type, so that
the difference in total -catenin levels in type III compared with
type I cells (Fig. 1b) was not attributable to failure to form this
characteristic complex. To determine whether it is possible to
restore Tcf transcriptional activity in type I latency, we inhibited
GSK3 activity with LiCl, a well known activator of the Wnt
pathway (3). In the presence of LiCl, Tcf transcriptional activity
is significantly higher in type I latency (Fig. 4b), which indicates
that the destruction complex is functional in these cells.
Our experiments suggest that in B cells infected with EBV and
with established type I latency, practically all expressed -cate-
nin is rapidly degraded. The observation that in type III latent
EBV infection -catenin is stabilized (Figs. 1 and 2) suggests that
a tumor virus is able to influence the -catenin pathway by
inhibiting -catenin degradation. On the other hand, virus
products in type III latency do not influence the expression of
components of the -catenin phosphorylation complex nor do
they prevent complex assembly (Fig. 4a). We thus examined
other steps in the destruction process.
Ubiquitination is an essential step in proteasomal degradation
(13). To determine whether there is a difference in -catenin
ubiquitination in latency I and III, we treated Sav I and Sav III
cells with the proteasomal inhibitor MG101 (ALLN), which
normally results in the accumulation of ubiquitinated -catenin
(24, 25). In the presence of MG101, type I latency cells accu-
mulate ubiquitinated -catenin, whereas the same cells with
latency III phenotype do not (Fig. 4c). The interest in biological
antagonists of ubiquitinating enzymes, DUBs, has been growing
recently. Herpesvirus-associated ubiquitin-specific protease can
remove ubiquitin from p53 (17), whereas the DUB FAM (fat
facets in mouse) can stabilize -catenin (25). However, we could
find no evidence of FAM protein expression in human B cells
(data not shown). It is possible that DUB expression is tissue-
and cell-specific.
The activity of DUBs in complex samples such as mammalian
cell extracts has been difficult to examine. Recently a new
chemistry-based proteomics approach has allowed demonstra-
tion of DUB activity with specific active-site-directed probes
against this group of enzymes (21). The active-site-directed
probes, which contain an epitope-tagged ubiquitin (HAUb), can
covalently modify only active DUBs. To determine whether
cytoplasmic -catenin can form a complex with DUBs we used
the HAUbVME probe, which has broad reactivity (21), because
we did not know which active DUB (or DUBs), if any, might be
associated with -catenin in our model system. Fig. 5a shows that
stable cytoplasmic -catenin is in the complex with active DUBs
in cells with latency III. To investigate whether inhibition of
DUB activity can influence -catenin stabilization, we used a
potential inhibitor of many DUBs, Ubal. Previously it has been
shown that at concentrations 3 M, Ubal increases ATP-
Fig. 3. (a) -CateninTcf transcriptional activity is higher in latency III. Sav I
and Sav III cells were transfected with luciferase reporter plasmids containing
WT (TOPFLASH) or mutated (FOPFLASH) Tcf promoter. After 48 h cells were
collected, and Tcf activity was determined by a luciferase assay. The data
represent the average fold induction of TOPFLASHFOPFLASH for each cell
line from two independent experiments prepared in duplicate. (b) Tcf protein
levels are similar in type I and type III latency. Total protein extracts of Sav I and
Sav III cells were probed with Tcf and actin antibodies.
Fig. 4. (a) Destruction complex of -catenin exists in both type I and type III
latency. Immunoprecipitation from cell extracts of Sav I and Sav III cell lines was
performed with Axin antibody. The components of the complex were de-
tected with Axin, GSK3, and APC antibodies. (b) Destruction complex of
-catenin is functional in type I latency. Sav I cells were transfected with
luciferase reporter plasmids containing WT (TOPFLASH) or mutated (FOP-
FLASH) Tcf promoter after treatment with 20 mM LiCl. After 48 h cells were
collected, and Tcf activity was determined by luciferase assay. (C) Ubiquiti-
nated -catenin is detected in latency I but not in latency III. Sav I and Sav III
cells were incubated with 25 M MG101 for 4 h at 37°C. Western blot of total
lysates was probed with -catenin antibody.
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dependent proteasomal degradation of different proteins (26).
Fig. 5b shows that after incubation with 1 M Ubal, the
-catenin level in Sav III cells is decreased, which indicates that
inhibition of DUB activity leads to an increase in -catenin
degradation.
Accumulation of -catenin can be the result of different
processes. For example, mutations in the APC tumor suppressor
or in -catenin itself trigger -catenin accumulation in many
human carcinomas, mostly those of colon and skin (10, 27, 28).
Mutations in the Axin gene leading to -catenin accumulation
have been detected in hepatocellular carcinomas and cerebellar
medulloblastomas (29, 30). All these mutations result in reduced
degradation of -catenin, which is believed to promote tumor
formation by constitutive activation of -catenin targets (2).
Another pathway leading to -catenin stabilization is the acti-
vation of Wnt signaling (31). Wnt genes are tumorigenic in mice
(32) and also may be implicated in human cancer (2). Most
results deal with carcinogenesis in epithelial cells, but almost
nothing is known in lymphoid cells.
In this article we identify a means whereby -catenin can be
stabilized in cells, specifically lymphoid cells, namely by a
tumor virus, EBV, through the inhibition of -catenin degra-
dation. Our results further suggest that deubiquitination may
enable -catenin stabilization and activation in type III latent
infection (Fig. 6). In future experiments, we plan to identify
and study the function and activity of the DUBs involved. It is
possible that different EBV gene products and proteins en-
coded by other viruses also may produce such effects. We have
preliminary evidence that the Epstein–Barr nuclear antigen 2
(EBNA2), which is essential for immortalization of cells by
EBV, may be involved in -catenin stabilization (data not
shown).
From the EBV perspective, a scenario could be constructed as
follows. In type I latency, -catenin is degraded as expected and
therefore cannot affect transforming potential by activating
cell-proliferation genes. However, type I latency is invariably
found only in Burkitt’s lymphoma. In Burkitt’s lymphoma, the
c-myc oncogene is already dysregulated by characteristic chro-
mosomal translocations that are the hallmark of this lymphoma,
even in the absence of EBV (5, 6). Therefore, -catenin stabi-
lization would presumably contribute little. In contrast, in type
III latency that characterizes lymphoproliferative diseases
caused by EBV, mutations affecting c-myc expression are not
found. Rather, presumably the virus exerts a stabilizing effect on
-catenin, thus making it available for activation of cell-
proliferation genes such as c-myc or cyclin D and perhaps partly
explaining the role of EBV in the genesis of lymphomatous
conditions.
Note Added in Proof. Since acceptance of this paper, Morrison et al. (33)
have reported that EBV latent membrane protein 2A activates -catenin
in epithelial cells through the PI3AKT pathway.
We are grateful to H. Ovaa (Harvard Medical School, Boston) and H.
Ploegh (Harvard Medical School) for providing the HAUbVME probe
and M. Peifer and R. Duronio for critical reading of the manuscript. This
work was supported by National Cancer Institute Grant CA 19014.
1. Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler,
K. W., Vogelstein, B. & Clevers, H. (1997) Science 275, 1784–1787.
2. Polakis, P. (2000) Genes Dev. 14, 1837–1851.
3. Barker, N. & Clevers, H. (2000) BioEssays 22, 961–965.
4. Pagano, J. S. (1999) Proc. Assoc. Am. Physicians 111, 573–580.
5. Katz, B. Z., Raab-Traub, N. & Miller, G. (1989) J. Infect. Dis. 160, 589–598.
6. Kieff, E. & Rickinson, A. (2001) Fields Virology, eds. Knipe, D. M. & Howley,
P. M. (Lippincott, Philadelphia), 4th Ed., pp. 2511–2573.
7. Kaiser, C., Laux, G., Eick, D., Jochner, N., Bornkamm, G. W. & Kempkes, B.
(1999) J. Virol. 73, 4481–4484.
8. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T.,
Morin, P. J., Vogelstein, B. & Kinzler, K. W. (1998) Science 281, 1509–
1512.
9. Tetsu, O. & McCormick, F. (1999) Nature 398, 422–426.
10. Morin, P. J. (1999) BioEssays 21, 1021–1030.
11. Reya, T., O’Riordan, M., Okamura, R., Devaney, E., Willert, K., Nusse, R. &
Grosschedl, R. (2000) Immunity 13, 15–24.
12. Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K.,
Hintz, L., Nusse, R. & Weissman, I. L. (2003) Nature 423, 409–414.
13. Hershko, A. & Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425–479.
Fig. 5. (a) -Catenin is present in a complex with active DUBs. Sav III cell
lysates were lysed in labeling buffer as described in Materials and Methods
and incubated with HAUbVME active-site-directed probe for 1 h at 37°C. After
immunoprecipitation (IP) with HA antibody, protein complexes were pulled
down with AG PLUS-Agarose, and Western blot was probed with -catenin
antibody. (b) Inhibition of DUB activity by Ubal leads to an increase of
-catenin degradation. Sav III cell lysates were incubated with Ubal probe for
2 h at 37°C. Western blots of total protein extracts were probed with -catenin
and actin antibodies.
Fig. 6. Stabilization of -catenin by EBV in type III latency. In type I EBV
latency -catenin is rapidly degraded. In type III latency EBV activates the
-catenin pathway by stabilizing -catenin through inhibition of proteasomal
degradation. Deubiquitination, at least in part, is involved in -catenin stabi-
lization and activation in type III latency EBV-infected cells.








14. Kim, J. H., Park, K. C., Chung, S. S., Bang, O. & Chung, C. H. (2003)
J. Biochem. 134, 9–18.
15. Wilkinson, K. D. (2000) Semin. Cell. Dev. Biol. 11, 141–148.
16. Chung, C. H. & Baek, S. H. (1999) Biochem. Biophys. Res. Commun. 266,
633–640.
17. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J. & Gu, W. (2002)
Nature 416, 648–653.
18. Bignell, G. R., Warren, W., Seal, S., Takahashi, M., Rapley, E., Barfoot, R.,
Green, H., Brown, C., Biggs, P. J., Lakhani, S. R., et al. (2000) Nat. Genet. 25,
160–165.
19. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D. &
Courtois, G. (2003) Nature 424, 801–805.
20. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A. &
Mosialos, G. (2003) Nature 424, 793–796.
21. Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson, K. D., Ploegh,
H. L. & Kessler, B. M. (2002) Chem. Biol. 9, 1149–1159.
22. Nonkwelo, C., Skinner, J., Bell, A., Rickinson, A. & Sample, J. (1996) J. Virol.
70, 623–627.
23. Fujimuro, M., Wu, F. Y., ApRhys, C., Kajumbula, H., Young, D. B., Hayward,
G. S. & Hayward, S. D. (2003) Nat. Med. 9, 300–306.
24. Danilkovitch-Miagkova, A., Miagkov, A., Skeel, A., Nakaigawa, N., Zbar, B.
& Leonard, E. J. (2001) Mol. Cell. Biol. 21, 5857–5868.
25. Taya, S., Yamamoto, T., Kanai-Azuma, M., Wood, S. A. & Kaibuchi, K. (1999)
Genes Cells 4, 757–767.
26. Shaeffer, J. R. & Cohen, R. E. (1996) Biochemistry 35, 10886–10893.
27. Chan, E. F., Gat, U., McNiff, J. M. & Fuchs, E. (1999) Nat. Genet. 21,
410–413.
28. Oving, I. M. & Clevers, H. C. (2002) Eur. J. Clin. Invest. 32, 448–457.
29. Clevers, H. (2000) Nat. Genet. 24, 206–208.
30. Baeza, N., Masuoka, J., Kleihues, P. & Ohgaki, H. (2003) Oncogene 22,
632–636.
31. Peifer, M. & Polakis, P. (2000) Science 287, 1606–1609.
32. Nusse, R. & Varmus, H. E. (1992) Cell 69, 1073–1087.
33. Morrison, J. A., Klingelhutz, A. J. & Raab-Traub, N. (2003) J. Virol. 77,
12276–12284.
15576  www.pnas.orgcgidoi10.1073pnas.2636947100 Shackelford et al.
